Piramal Pharma Ltd. Improves ESG Rating to 64 for FY 2024-25

Piramal Pharma Ltd. has been assigned an Environment, Social, and Governance (ESG) Rating of ‘64’ for the FY 2024-25 by NSE Sustainability Ratings and Analytics Limited. This marks an improvement over the previous score of 61, reflecting the company's commitment to sustainability and responsible operations. The rating is based on data made available by the company in the public domain. Notably, the company did not engage NSE Sustainability for this rating; it was voluntarily prepared by NSE Sustainability considering the ESG factors reported by the company.